Followers | 62 |
Posts | 3433 |
Boards Moderated | 0 |
Alias Born | 08/11/2015 |
![](https://investorshub.advfn.com/uicon/538908.png?cb=1471567874)
Monday, August 15, 2016 5:02:43 PM
August 15, 2016 9:46 AM
Leerink Partners reiterated an Outperform rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) following the release of top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients with active lupus nephritis (LN). Analyst Joseph P. Schwartz noted that the study hit on efficacy.
In the analyst's view, the stock is down significantly as a result of an excess number of deaths for patients receiving the drug. However, he thinks it is important to be mindful that these lupus nephritis patients were extremely sick and treated at many sites. The company noted that there were no clear underlying patterns among the deaths.
"The Ph.2b AURA study investigating voclosporin in lupus nephritis (LN) pts. met its primary endpoint of complete remission (CR; p=0.045) and improvements in partial remission (PR; p=0.007) vs. pbo. While efficacy was higher among pts. receiving the low dose, the high-dose cohort also achieved meaningful improvements in PR (p=0.024). Meanwhile, the stock is trading down due to more deaths (n=10) for patients in the low-dose cohort, which the company attributes to the severe underlying nature of the disease," said Schwartz.
"CR, defined as urinary protein/creatinine ratio of ≤0.5 mg/ mg at 24 weeks, was noticeably higher among voclosporin-receiving pts. -- 32.6% (low-) and 27.3% (high-dose) -- compared to 19.3% seen in pbo. arm. Efficacy in PR (50% reduction in UPCR vs. baseline) also favored voclosporin -- 69.7% (low-; p=0.007) and 65.9% (high-dose; p=0.024) -- vs. 49.4% in pbo. arm. It is also worth noting that time to CR and PR were both shorter for voclosporin groups, which substantiates the response rates," continued the analyst.
Commenting on its adverse event profile, the analyst said, "Unlike the overall rate of adverse events (AEs), a higher rate of serious AEs (SAEs) was observed in both voclosporin arms, an observation consistent with highly active disease. There were 13 reported deaths, 12 of which were in the voclosporin arms (2 in high-dose vs. 10 in low-dose) and 11/13 occurred in Asia. Although details are lacking at this early stage of data analysis, mgmt. noted 3 possible reasons: 1) randomization resulted in more Asian pts. receiving low-dose voclosporin, 2) differences in pt. management/ lack of treatment, and 3) severity of underlying disease. Whereas the noticeably higher deaths in voclosporin arms obviously triggers some caution among investors, we look forward to future updates. Management noted there were four deaths due to infection in the low dose, and a smattering of other causes related to lupus, some very soon after entering the study, and all resembling the underlying cause of disease."
Schwartz continued, "At first glance, the efficacy seen in the drug arms looks lower than what we had expected, but still respectable. The study was 80% powered to detect a remission rate of 41% for the drug versus 20% for placebo based on a planned sample size of 258 subjects. CR rates as low as 35% vs. 15% or as high as 47% versus 25% would also maintain 80% power. The reverse dose response was surprising, particularly since this would have been pulled down by accounting for the relatively high number of deaths in the drug arm."
http://www.streetinsider.com/dr/news.php?id=11938729
Recent AUPH News
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 07/02/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:28 PM
- Aurinia Announces 2024 Annual General Meeting Results • Business Wire • 06/14/2024 04:16:00 PM
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 • Business Wire • 06/05/2024 10:00:00 AM
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce • Business Wire • 06/04/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 09:25:39 PM
- Aurinia Provides Update on Proxy Statement • Business Wire • 06/03/2024 10:30:00 PM
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:11:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:07:15 PM
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 • Business Wire • 05/14/2024 10:00:00 AM
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 • Business Wire • 05/09/2024 10:00:00 AM
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 10:00:00 AM
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results • Business Wire • 05/02/2024 10:00:00 AM
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month • Business Wire • 05/01/2024 10:00:00 AM
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program • Business Wire • 04/30/2024 10:00:00 AM
- New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/16/2024 02:48:00 PM
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 • Business Wire • 04/15/2024 10:00:00 AM
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/09/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:44:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:43:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:42:46 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM